JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2007, 56(6):269-275

A study of the properties of tablets from coprocessed dry binders composed of α-lactose monohydrate and different types of cellulose

J. Mužíková, J. Zvolánková
Department of Pharmaceutical Technology, Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Czech Republic

The paper evaluates the differences between the properties of tablets from two coprocessed dry binders based on α-lactose monohydrate and cellulose, MicroceLac®100 and Cellactose®80. The substances differ in the type of contained cellulose; MicroceLac®100 contains 25% of microcrystalline cellulose, Cellactose®80, 25% of powdered cellulose. The properties under study included the tensile strength and disintegration time in dependence on compression force, addition of two concentrations of the lubricant sodium stearylfumarate (Pruv) and a 50% addition of the active ingredients ascorbic acid and acetylsalicylic acid. Using one of the compression forces, the effect of Pruv and magnesium stearate on the above-mentioned properties were compared. In the compression forces of 6 and 8 kN the strength of the compacts from pure Cellactose®80 was lower than that of those from MicroceLac®100 both without and with the lubricant. The lubricant sensitivity of dry binders depended on compression force. Pruv decreased the strength of compacts less than magnesium stearate. The tablets from Cellactose®80 possessed a longer disintegration time than those from MicroceLac®100, excepting the tableting materials containing 0.4 Pruv with a compression force of 6 kN. Disintegration time was prolonged with the use of sodium stearylfumarate and it was increased with compression force much more markedly in the case of Cellactose®80. In the presence of ascorbic acid, the strength of tablets was decreased in the case of both dry binders, but it was higher with MicroceLac100, disintegration time was very short and independent of the type of the dry binder. In the case of acetylsalicylic acid, the strength of tablets was higher with a lesser influence of the type of the dry binder, and disintegration time was longer and especially in the case of Cellactose®80 increased with increasing concentration of Pruv.

Keywords: MicroceLac®100; Cellactose®80; sodium stearyl fumarate; magnesium stearate; ascorbic acid; acetylsalicylic acid; tensile strength of tablets; disintegration time of tablets

Received: August 17, 2007; Accepted: October 8, 2007; Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mužíková J, Zvolánková J. A study of the properties of tablets from coprocessed dry binders composed of α-lactose monohydrate and different types of cellulose. Čes. slov. farm. 2007;56(6):269-275.
Download citation

References

  1. Garr, J. S. M., Rubinstein, M. H.: Pharm. Tech. Int., 1991; 3, 24-27.
  2. Jarosz, P. J., Parrott, E. L.: Drug Dev. Ind. Pharm., 1984; 10, 259-273. Go to original source...
  3. Belda, P. M., Mielck, J. B.: J. Pharm. Biopharm., 1996; 42, 325-330.
  4. Bolhuis, G. K., Chowhan, Z. T.: Materials for direct compaction. In: Alderborn, G., Nyström, Ch. eds. Pharmaceutical Powder Compaction Technology, New York, Marcel Dekker, Inc., 1996, p. 419-500. Go to original source...
  5. Reimerdes, D., Aufmuth, K. P.: Manuf. Chem., 1992; 63, 21-24. Go to original source...
  6. Casalderrey, M., Souto, C., Concheiro, A. et al.: Chem. Pharm. Bull., 2000; 48, 458-463. Go to original source... Go to PubMed...
  7. Meggle GmbH MicroceLac®100. Firm. Lit., http://megglepharma.innet.de/en/products/uebersicht/microcelac100/,2005-11-08.
  8. Michoel, A., Rombaut, P., Verhoye, A.: Pharm. Dev. Tech., 2002; 7, 79-87. Go to original source... Go to PubMed...
  9. Fell, J. T., Newton, J. M.: J. Pharm. Sci., 1970; 59, 688691. Go to original source... Go to PubMed...
  10. Bos, C. E., Bolhuis, H., Van Doorne, Lerk, C. F.: Pharm. Weekbl. Sci. Ed., 1987; 9, 274-282. Go to original source... Go to PubMed...
  11. Belousov, V. A.: Khim. Farm. Zh. 1976; 10, 105-111. Go to original source...
  12. Lamberson, R. L., Raynor, G. E.: Man. Chem. Aerosol News, 1976; 47, 55.
  13. Ferrari, F., Bertoni, M., Bonferoni, M. C. et al.: Int. J. Pharm., 1996; 136, 71-79. Go to original source...
  14. Muzikova, J., Palenik, L.: Čes. slov. Farm., 2005; 54, 118-122.
  15. Bolhuis, G. K., Hölzer, A. W.: Lubricant sensitivity. In: Alderborn, G. Nyström, Ch. eds. Pharmaceutical Powder Compaction Technology, New York, Marcel Dekker, Inc., 1996, s. 517-560. Go to original source...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.